BGM1812

BGM1812 is a long-acting amylin analog under development for metabolic diseases. Amylin is a 37-amino acid peptide hormone co-secreted with insulin by pancreatic beta cells. It plays a role in glycemic control by inhibiting gastric emptying and controlling appetite, which leads to both hypoglycemic and weight loss effects. BGM1812 aims to leverage these properties for the treatment of diabetes and potentially obesity. The drug is being developed as part of an innovative approach to metabolic disease management, where combination regimens (such as pairing amylin analogs with GLP-1 receptor agonists) are increasingly explored for synergistic benefits in blood sugar control and weight reduction[4][1].